DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
WESTLAKE VILLAGE, Calif., Feb. 23, 2018 -- MannKind Corporation (Nasdaq:MNKD) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on February 27, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 46307898. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4630 7898#. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[email protected]
